BMEA · Biomea Fusion, Inc.
$2.03
+0.12 (+6.28%)
At close · Sep 4
Going-concern doubt
— flagged Aug 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the preparation of this Quarterly Report on Form 10-Q for the period ended June 30, 2026, our management has concluded that there is substantial doubt as to whether we can continue as a going concern for the twelve months following the issuance of this Quarterly Report on Form 10-Q. Our ability to continue as a going concern is dependent upon raising capital to maintain current operations and continue research and development efforts. We plan to raise additional capital to fund our operations through public or private equity offerings, debt financings, and/or potential collaborations and license arrangement or other sources. There is no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed or that we will be able to obtain financing or enter into a collaboration on terms acceptable to us. Based on our current operating plan, we will not be able to continue as a going concern over the next twelve months unless we raise additional capital by other means. These factors raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 5, 2026
Market Cap
$147.14M
Shares
72.48M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.03
Open$1.90
Day$1.89–2.05
52W close$0.96–2.67
Avg vol 30d1.4M
Short int9.8M · 13.5% float · 20.9d
Short vol34%
Last earningsMay 5, 2026
DataApr 2021–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Sep 29, 2026
Est · unconfirmed
· in 3 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$32.54M
Trailing 12 months
Revenue growth YoY
+0.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+78.1%
Year over year · more shares
Price change (1Y)
+10.9%
Trailing year
Short interest
13.5%
Latest settlement · 20.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+48%
above
Price vs 50-day avg
+45%
above
RSI (14)
81
overbought
MACD trend
Positive
52-week position
63%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+61%
trailing
6-month return
+62%
trailing
YTD return
+64%
this year
Relative strength
+47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-5% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.55% of float · ▼ -2.0% MoM · 20.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
62 holders — near 3-yr low, contrarian setup
Squeeze score
89
high risk · 0–100
Fundamentals
EPS growth
+69%
Y/Y
Free cash flow
$-70.7M
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+48%
Bullish
Price vs 50-day avg
+45%
Bullish
RSI (14)
81
Bearish
MACD trend
Positive
Bullish
52-week position
63%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-5% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
13.55% of float · ▼ -2.0% MoM · 20.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
62 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $2 · 63%
Range high $3
vs 200-day avg +48%
vs 50-day avg +45%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMEA
this stock
Biomea Fusion, Inc.
|
$147.14M | +63.7% | — | — | 13.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.42B | +20.5% | +46.2% | 31.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.22B | +7.2% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$64.25B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMEA | +17.3% | +61.1% | +62.4% | +20.8% | +63.7% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +17.2% | +61.5% | +47.3% | +20.4% | +50.8% |
Key facts
CIK
1840439
CUSIP
09077A106
13F (30d)
44 filings
44 filers
Visit website
Investor relations